EBF3 and metastatic neoplasm: Increased methylation of a CpG site in the EBF3 promoter in primary and metastatic tumours (cg02700606, which is 396 bp from the RRBS fragment previously analysed [9] and additional sites examined) was consistent with previously published data showing significant hypermethylation of the EBF3 promoter in metastatic melanoma cell lines [9].